ReviewMultiple sclerosis and related disorders2020
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Review in Multiple sclerosis and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis.Revue neurologiquePooled it
- Neutrophils in the Spotlight-An Analysis of Neutrophil Function and Phenotype in ARDS.International journal of molecular sciences · 2024Article
- Review
- Use of chronic medications and risk of death due to COVID-19 in hospitalised patients.European journal of hospital pharmacy : science and practice · 2024Article
- Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.Journal of neurology · 2023Article
- COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.Journal of clinical medicine · 2023Article
- The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.Multiple sclerosis and related disorders · 2023Review
- Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis.Current microbiology · 2022Review
- SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.Journal of neurology · 2022Review
- Multiple Sclerosis Management During the COVID-19 Pandemic.Current neurology and neuroscience reports · 2022Review
- How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?Multiple sclerosis and related disorders · 2022Article
- SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal.Multiple sclerosis and related disorders · 2022Article
- Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?Clinical and experimental immunology · 2022Article
- Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.Journal of neurology · 2022Article
- Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.Journal of neurology · 2022Article
- Multiple sclerosis patients' response to COVID-19 pandemic and vaccination in Egypt.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Article
- COVID-19 Outcomes in Myasthenia Gravis Patients: Analysis From Electronic Health Records in the United States.Frontiers in neurology · 2022Article
- Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.Current neuropharmacology · 2022Article
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.Neurology · 2021Article
- Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.Journal of neuroimmunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS.
objectiveTo examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.